Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

Published:2024-08 Issue: Volume: Page:
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Lu Brandon,Dvorani Erind,Nguyen Lena,Beca Jaclyn M.,Mercer Rebecca E.,Adamic Andrea,Muñoz Caroline,Chan Kelvin K.W.

Funder

Ministry of Long-Term Care

Institute for Clinical Evaluative Sciences

Ministry of Health, Ontario

Ontario Institute for Cancer Research

Ontario Ministry of Health and Long-Term Care

Kementerian Kesihatan Malaysia

Publisher

Elsevier BV

Reference33 articles.

1. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars;Henry;Semin Oncol,2014

2. Clinical and regulatory considerations for the use of bevacizumab biosimilars in metastatic colorectal cancer;Taïeb;Clin Colorectal Cancer,2021

3. Efficacy and safety of the biosimilar ABP 215 compared with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (MAPLE): a randomized, double-blind, phase III study;Thatcher;Clin Cancer Res,2019

4. PF-06439535 (a bevacizumab biosimilar) compared with reference bevacizumab (Avastin®), both plus paclitaxel and carboplatin, as first-Line treatment for advanced non-squamous non-small-cell lung cancer: a randomized, double-blind study;Reinmuth;BioDrugs,2019

5. Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland;Carl;JAMA Netw Open,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP